Key result
Angptl2 overexpression increased, while Angptl2 knockout and Angptl2 siRNA injection significantly reduced, corneal hemangiogenesis and lymphangiogenesis in sutured mouse corneas.
Why the study?
Does Angptl2 modulation affect corneal hemangiogenesis and lymphangiogenesis in a mouse model of corneal inflammation?
Does Angptl2 modulation affect corneal hemangiogenesis and lymphangiogenesis in a mouse model of corneal inflammation?
Angptl2 is upregulated in corneal inflammation and drives hemangiogenesis and lymphangiogenesis, suggesting it may be a therapeutic target for preventing blindness.
Angptl2 modulates corneal angiogenesis in mice; hypothesis-generating for targeted inhibition but leaves open human relevance.
PURPOSE: We determined the plausible functional role of angiopoietin-like protein 2 (Angptl2) in inflammatory corneal hemangiogenesis and lymphangiogenesis in vivo. METHODS: Corneal hemangiogenesis and lymphangiogenesis were induced by suturing 10-0 nylon 1 mm away from the limbal vessel in Angptl2 knockout and K14-Angptl2 transgenic mice. We analyzed Angptl2 and interleukin 1β (IL-1β) expressions in normal and vascularized corneas by real-time RT-PCR and immunohistochemistry. Corneal hemangiogenic and lymphangiogenic responses, and macrophage infiltration were assessed by immunofluorescent microscopic studies using specific antibodies against CD31, LYVE-1, and F4/80, and compared to their corresponding background. Subconjunctival injection of Angptl2 siRNA to the sutured corneas was also performed. RESULTS: Angptl2 mRNA expression increased markedly in the neovascularized corneas compared to the normal cornea. Angptl2 protein was expressed strongly in the corneal epithelium and stroma of the vascularized cornea. The regions showing hemangiogenesis and lymphangiogenesis were increased significantly in K14-Angptl2 mice and reduced in Angptl2(-/-) mice compared to their corresponding background strains. In contrast to control mice, the number of F4/80-positive cells, as well as the expressions of F4/80 and IL-1β were found to be higher in K14-Angptl2 mice and lower in Angptl2(-/-) mice. Subconjunctival injection of Angptl2 siRNA significantly inhibited hemangiogenesis and lymphangiogenesis in the sutured corneas. CONCLUSIONS: Our findings demonstrated Angptl2 to be upregulated in corneal inflammation, and highlight that corneal hemangiogenesis and lymphangiogenesis may be driven by Angptk2 overexpression via macrophage infiltration and IL-1β expression. Angptl2 may be a novel therapeutic target for preventing blindness.
No takes yet. Share an insight, caveat, or question.
Toyono et al. (2013) studied Corneal inflammation, hemangiogenesis, and lymphangiogenesis. Angptl2 genetic modification (knockout/overexpression) and Angptl2 siRNA vs. Corresponding background strains / control mice was evaluated on Corneal hemangiogenesis, lymphangiogenesis, and macrophage infiltration. Angptl2 overexpression increased, while Angptl2 knockout and Angptl2 siRNA injection significantly reduced, corneal hemangiogenesis and lymphangiogenesis in sutured mouse corneas.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: